GoAI
Get started
RenovoRx, Inc. logo

RenovoRx, Inc.

RNXT

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.32

$0.00 · 0.00%

Aug 21, 4:00 PM ET

RNXT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

72

Undervalued

Momentum

39

Weakening

Sentiment

62

Bullish

Risk resilience

36

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Shaun R. Bagai
Listed since
Aug 26, 2021
Employees
17

Market position

Day range

Current $1.32

52-week range

Current $1.32

Open
$1.3141
Previous close
$1.32
Volume
233.27K
0.74× average
Average volume
316.57K
Average daily volume
Market cap
59.47M USD
Beta
0.99
Market reference 1
50-day average
$0.9923
+33.02% above average
200-day average
$0.9457
+39.58% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
22.87M USD
P/E (TTM)
-4.17×
P/B (TTM)
6.95×
P/S (TTM)
30.1×
EV / EBITDA
-2.05×
Earnings yield
-37.62%
Free cash flow yield
-36.97%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
84.41%
Operating margin
-678.04%
Net margin
-621.71%
Return on equity
-205.98%
Return on assets
-137.96%
Return on invested capital
-200.55%

Financial health

Debt / equity
0.03×
Current ratio
4.02×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends2661%-7583%-17828%-28073%Gross margin, FY2024: 100.00%Gross margin, FY2025: 70.88%Operating margin, FY2024: -25511.63%Operating margin, FY2025: -1113.98%Net margin, FY2024: -20497.67%Net margin, FY2025: -994.48%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 100.00%. Gross margin FY2025 70.88%. Operating margin FY2024 -25511.63%. Operating margin FY2025 -1113.98%. Net margin FY2024 -20497.67%. Net margin FY2025 -994.48%.

Income trends

Revenue

1.12M USD+2511.63%

Operating income

−12.51M USD-14.04%

Net income

−11.17M USD-26.71%
Income trends across reported periods2.49M USD−2.97M USD−8.42M USD−13.87M USDRevenue, FY2024: 43K USDRevenue, FY2025: 1.12M USDOperating income, FY2021: −5.67M USDOperating income, FY2022: −9.95M USDOperating income, FY2023: −11.4M USDOperating income, FY2024: −10.97M USDOperating income, FY2025: −12.51M USDNet income, FY2021: −6.32M USDNet income, FY2022: −9.89M USDNet income, FY2023: −10.23M USDNet income, FY2024: −8.81M USDNet income, FY2025: −11.17M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 43K USD. Revenue FY2025 1.12M USD. Operating income FY2021 −5.67M USD. Operating income FY2022 −9.95M USD. Operating income FY2023 −11.4M USD. Operating income FY2024 −10.97M USD. Operating income FY2025 −12.51M USD. Net income FY2021 −6.32M USD. Net income FY2022 −9.89M USD. Net income FY2023 −10.23M USD. Net income FY2024 −8.81M USD. Net income FY2025 −11.17M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.12M USD43K USD———
Cost of goods sold327K USD————
Gross profit796K USD43K USD———
Research and development6.27M USD6.03M USD5.67M USD4.3M USD3.04M USD
Selling, general, and administrative7.04M USD4.99M USD5.73M USD5.65M USD2.63M USD
Operating expenses13.31M USD11.01M USD11.4M USD9.95M USD5.67M USD
Interest income427K USD384K USD—57K USD70K USD
Interest expense——108K USD57K USD904K USD
Depreciation and amortization2K USD—6K USD6K USD9K USD
Operating income−12.51M USD−10.97M USD−11.4M USD−9.95M USD−5.67M USD
Net income−11.17M USD−8.81M USD−10.23M USD−9.89M USD−6.32M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 1 miss, 6 met estimates
Average EPS surprise
+9.28%
11 comparable reports
Latest EPS result
-0.05
Estimate -0.07 · Beat by 31.03%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.04-0.09-0.13-0.17Q1 '25BeatQ2 '25MetQ3 '25MetQ4 '25MetQ1 '26MetQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -0.12, estimate -0.13, surprise +7.69%, Beat. Q2 2025, reported May 15, 2025: actual -0.08, estimate -0.08, surprise 0.00%, Met estimate. Q3 2025, reported Aug 14, 2025: actual -0.08, estimate -0.08, surprise 0.00%, Met estimate. Q4 2025, reported Nov 13, 2025: actual -0.08, estimate -0.08, surprise 0.00%, Met estimate. Q1 2026, reported Mar 30, 2026: actual -0.08, estimate -0.08, surprise 0.00%, Met estimate. Q2 2026, reported May 14, 2026: actual -0.08, estimate -0.08, surprise 0.00%, Met estimate. Q3 2026, reported Aug 12, 2026: actual -0.05, estimate -0.073, surprise +31.03%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.05, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.02M695.33K365.94K36.55KQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual 43K USD, estimate 167.5K USD, surprise -74.33%, Miss. Q2 2025, reported May 15, 2025: actual 197K USD, estimate 183.33K USD, surprise +7.46%, Beat. Q3 2025, reported Aug 14, 2025: actual 422K USD, estimate 304K USD, surprise +38.82%, Beat. Q4 2025, reported Nov 13, 2025: actual 266K USD, estimate 405.4K USD, surprise -34.39%, Miss. Q1 2026, reported Mar 30, 2026: actual 238K USD, estimate 419.7K USD, surprise -43.29%, Miss. Q2 2026, reported May 14, 2026: actual 563K USD, estimate 469.5K USD, surprise +19.91%, Beat. Q3 2026, reported Aug 12, 2026: actual 909K USD, estimate 703.75K USD, surprise +29.17%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 952K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

5 ratings
Strong buy00%
Buy480%
Hold120%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions
Maxim GroupdowngradeBuyHold

RNXT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding RNXT

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
991.07K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
364.08K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research RNXT

research.disclaimer